The Columbia University Digestive and Liver Disease Research Center
The Columbia University Digestive and Liver Disease Research Center
批准号:
10612948
负责人:
Robert F. Schwabe
金额:
$121.89万
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
未结题
起止时间:
2022-04-30 至 2027-03-31
关键词:
AppointmentAutomobile DrivingBasic ScienceBioinformaticsBiologyCell CommunicationCellsClinicalClinical ResearchCollaborationsCollectionCommunitiesCore FacilityCreativenessDataDatabasesDetectionDigestive System DisordersDirect CostsDisciplineDiseaseEducationEducational workshopEffectivenessEnsureEnvironmentEpithelial CellsEpitheliumEsophagusEvolutionFunctional disorderFundingFutureGoalsGrantGrowthHomeostasisHospitalsInflammationInstitutionJointsLinkLiverLiver diseasesMeasuresMentorsMetabolismMissionMorbidity - disease rateNational Institute of Diabetes and Digestive and Kidney DiseasesNatural regenerationNeoplasmsNew YorkOrganOrganoidsPancreasPathway interactionsPatientsPhysiologyPresbyterian ChurchPreventionProductivityPublicationsResearchResearch MethodologyResearch PersonnelScienceScientistServicesStructureTrainingTraining and EducationTranslationsUnited States National Institutes of HealthUniversitiesVisionbasebioimagingclinical applicationclinical translationclinically relevantdiversity and equityempowermentequity, diversity, and inclusionforginggastrointestinalimprovedinnovationinter-institutionalmembermortalitymultidisciplinarynext generationnovel therapeutic interventionpatient populationprogramssingle cell analysissuccesssymposiumtherapeutic target
中文摘要
总结
自2019年正式成立以来,哥伦比亚大学消化和肝病研究中心(CU-
DLDRC)汇集了一个跨学科的小组,高度完成的基础,翻译和临床
来自不同部门和校园以及纽约的互补背景的研究人员
长老会医院CU-DLDRC反映了过去两年消化系统疾病科学的蓬勃发展
几十年来,加上特殊的机构支持和哥伦比亚充满活力的科学环境,
大学CU-DLDRC的愿景是为改善消化道疾病的预防,检测和治疗做出贡献。
疾病通过应用创造性的概念,前沿的研究方法,创新和多,
学科团队科学,重点是临床相关性和翻译。CU-DLDRC包括
49个以消化为重点的成员(30个正式成员,19个副成员),NIH资助2080万美元的直接费用(35.6%来自
NIDDK)。中心主题“上皮细胞及其在消化系统稳态和疾病中的相互作用”,反映了
其成员的热情和专业知识及其在消化系统疾病中的关键作用。消化道的广泛覆盖
这一主题下的器官是基于概念框架,许多疾病驱动途径,细胞,
细胞相互作用和治疗靶点在消化器官中是共享的。在这些原则的指导下,
哥伦比亚的消化系统疾病研究见证了显着的增长和影响,富有成效的合作,
联合出版物和赠款的程度,将不会通过在单一消化器官的研究实现。
行政核心确保CU-DLDRC的成功和有效性,
研究基础、业务监督、科学愿景、创新,以及促进发展的结构和活动
翻译消化科学与最大的成员利益(目标1)。四个生物医学核心提供了一套
紧密相连的最先进的核心设施,从临床生物标本和数据库到切割-
边缘生物信息学,类器官平台和先进的生物成像,使成员能够研究
上皮细胞及其相互作用;这些强大的研究方法将与临床研究的广度联系起来。
通过以器官为中心的临床基础团队提供专业知识和生物标本(目标2)。试点和可行性方案,
迄今为止,该基金已资助了7名调查人员,回报率非常高,将促进有影响力的基本和
临床项目,从而促进新的研究者,创新和整合卓越的其他
领域(目标3)。丰富计划将促进我们中心内的知识交流,并与国家
通过研讨会,年度务虚会和基础临床研讨会消化社区;支持新的研究人员
通过正式的指导计划和研讨会进行培训;并促进多样性,公平和包容性
(DEI)通过环境倡议的一名代表,参与CU-DLDRC的所有组成部分和活动(目标4)。通过这些目标,
CU-DLDRC将为消化系统疾病研究做出有影响力的贡献,并为我们的患者服务。
英文摘要
SUMMARY
Since its formal inception in 2019, the Columbia University Digestive and Liver Disease Research Center (CU-
DLDRC) has brought together an interdisciplinary group of highly accomplished basic, translational and clinical
researchers with complementary backgrounds from different departments and campuses and the New York
Presbyterian Hospital. The CU-DLDRC reflects vibrant growth in digestive disease science over the last two
decades, paired with exceptional institutional support and a dynamic scientific environment at Columbia
University. The CU-DLDRC’s vision is to contribute to improved prevention, detection and therapy of digestive
diseases through the application of creative concepts, cutting-edge research methods, innovation and multi-
disciplinary team science, with a strong emphasis on clinical relevance and translation. The CU-DLDRC includes
49 digestive-focused members (30 full, 19 associate) with NIH funding of $20.8M direct costs (35.6% from
NIDDK). The central theme “Epithelial cells and their interactions in digestive homeostasis and disease”, reflects
the passion and expertise of its members and its key role in digestive diseases. The broad coverage of digestive
organs under this theme is predicated upon the conceptual framework that many disease-driving pathways, cell-
cell interactions and therapeutic targets are shared across digestive organs. Guided by these principles,
digestive disease research at Columbia has witnessed significant growth and impact, fruitful collaborations and
joint publications and grants to a degree that would not have been achieved by studies in single digestive organs.
The Administrative Core ensures success and effectiveness of the CU-DLDRC through management of its
research base, operational oversight, scientific vision, innovation, and structures and activities that stimulate
translational digestive science with maximum member benefits (Aim 1). The four biomedical cores offer a suite
of closely linked state-of-the-art core facilities that span from clinical biospecimens and databases to cutting-
edge bioinformatics, organoid platforms and advanced bioimaging, empowering members to investigate
epithelial cells and their interactions; these powerful research methods will be linked the breadth of clinical
expertise and biospecimens via organ-focused clinical-basic teams (Aim 2). The Pilot and Feasibility program,
that to date has funded seven investigators with an exceptional rate of return, will promote impactful basic and
clinical projects, thereby promoting new investigators, innovation and the integration of excellence from other
fields (Aim 3). The Enrichment Program will stimulate intellectual exchange within our center and with the national
digestive community through seminars, an annual retreat, and basic-clinical symposia; support new investigators
and training through a formal mentoring program and workshops; and promote Diversity, Equity and Inclusion
(DEI) in all components and activities of the CU-DLDRC through a DEI delegate (Aim 4). Through these Aims,
the CU-DLDRC will make impactful contributions to digestive disease research and serve our patients.
期刊论文(20)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.1136/gutjnl-2021-324209
发表时间:
2022-06
期刊:
GUT
影响因子:
24.5
作者:
[Bergman, David, King, James, Lebwohl, Benjamin, Clements, Mark S., Roelstraete, Bjorn, Kaplan, Gilaad G., Green, Peter H. R., Murray, Joseph A., Ludvigsson, Jonas F.]
通讯作者:
Ludvigsson, Jonas F.
DOI:
10.1016/j.jcmgh.2022.09.008
发表时间:
2023
期刊:
CELLULAR AND MOLECULAR GASTROENTEROLOGY AND HEPATOLOGY
影响因子:
7.2
作者:
[Kim, Kwang H., Park, Jihwan, Cho, Yejin, Cho, Soo Young, Lee, Buhyun, Jeong, Haengdueng, Lee, Yura, Yi, Ja-Woon, Oh, Yeseul, Lee, Jin-Jae, Wang, Timothy C., Lim, Kyung-Min, Nam, Ki Taek]
通讯作者:
Nam, Ki Taek
DOI:
10.1007/s00259-021-05582-y
发表时间:
2022-05
期刊:
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
影响因子:
9.1
作者:
[Fang, Hsin-Yu, Stangl, Stefan, Marcazzan, Sabrina, Carvalho, Marcos J. Braz, Baumeister, Theresa, Anand, Akanksha, Strangmann, Julia, Huspenina, Julia Slotta, Wang, Timothy C., Schmid, Roland M., Feith, Marcus, Friess, Helmut, Ntziachristos, Vasilis, Multhoff, Gabriele, Gorpas, Dimitris, Quante, Michael]
通讯作者:
Quante, Michael
DOI:
10.1001/jamanetworkopen.2023.43392
发表时间:
2023-11-01
期刊:
JAMA NETWORK OPEN
影响因子:
13.8
作者:
[Aziz, Zainab, Wagner, Sophie, Agyekum, Alice, Pumpalova, Yoanna S., Prest, Matthew, Lim, Francesca, Rustgi, Sheila, Kastrinos, Fay, Grady, William M., Hur, Chin]
通讯作者:
Hur, Chin
DOI:
10.1136/gutjnl-2021-326645
发表时间:
2022-11
期刊:
GUT
影响因子:
24.5
作者:
[Schiepatti, Annalisa, Sanders, David S., Baiardi, Paola, Caio, Giacomo, Ciacci, Carolina, Kaukinen, Katri, Lebwohl, Benjamin, Leffler, Daniel, Malamut, Georgia, Murray, Joseph A., Rostami, Kamran, Rubio-Tapia, Alberto, Volta, Umberto, Biagi, Federico]
通讯作者:
Biagi, Federico
共 14 条
The Columbia University Digestive and Liver Disease Research Center
-
批准号:10443133
-
项目类别:
-
资助金额:$122.99万
-
财政年份:2022
-
负责人:Robert F. Schwabe
-
依托单位:
The Administrative Core
-
批准号:10443134
-
项目类别:
-
资助金额:$24.56万
-
财政年份:2022
-
负责人:Robert F. Schwabe
-
依托单位:
The Administrative Core
-
批准号:10612949
-
项目类别:
-
资助金额:$24.62万
-
财政年份:2022
-
负责人:Robert F. Schwabe
-
依托单位:
Tumor-promoting and tumor-suppressive roles of Hepatic Stellate Cell Subpopulations in NASH-HCC
-
批准号:10278434
-
项目类别:
-
资助金额:$53.5万
-
财政年份:2021
-
负责人:Robert F. Schwabe
-
依托单位:
Protective and fibrosis-independent functions of hepatic stellate cells
-
批准号:10597076
-
项目类别:
-
资助金额:$51.8万
-
财政年份:2021
-
负责人:Robert F. Schwabe
-
依托单位:
Protective and fibrosis-independent functions of hepatic stellate cells
-
批准号:10378664
-
项目类别:
-
资助金额:$53.22万
-
财政年份:2021
-
负责人:Robert F. Schwabe
-
依托单位:
Tumor-promoting and tumor-suppressive roles of Hepatic Stellate Cell Subpopulations in NASH-HCC
-
批准号:10454375
-
项目类别:
-
资助金额:$51.51万
-
财政年份:2021
-
负责人:Robert F. Schwabe
-
依托单位:
Tumor-promoting and tumor-suppressive roles of Hepatic Stellate Cell Subpopulations in NASH-HCC
-
批准号:10654714
-
项目类别:
-
资助金额:$50.19万
-
财政年份:2021
-
负责人:Robert F. Schwabe
-
依托单位:
DAMPs and Their Receptors Link Hepatocyte Death to HSC Activation and Liver Fibrosis
-
批准号:10224799
-
项目类别:
-
资助金额:$52.0万
-
财政年份:2019
-
负责人:Robert F. Schwabe
-
依托单位:
DAMPs and Their Receptors Link Hepatocyte Death to HSC Activation and Liver Fibrosis
-
批准号:9917105
-
项目类别:
-
资助金额:$52.0万
-
财政年份:2019
-
负责人:Robert F. Schwabe
-
依托单位:
DAMPs and Their Receptors Link Hepatocyte Death to HSC Activation and Liver Fibrosis
-
批准号:10453767
-
项目类别:
-
资助金额:$52.0万
-
财政年份:2019
-
负责人:Robert F. Schwabe
-
依托单位:
DAMPs and Their Receptors Link Hepatocyte Death to HSC Activation and Liver Fibrosis
-
批准号:10021026
-
项目类别:
-
资助金额:$52.0万
-
财政年份:2019
-
负责人:Robert F. Schwabe
-
依托单位:
TAZ and YAP in Non-Alcoholic Steatohepatitis and its Complications
-
批准号:9473156
-
项目类别:
-
资助金额:$66.41万
-
财政年份:2018
-
负责人:Robert F. Schwabe
-
依托单位:
FASEB SRC on Liver Biology: Fundamental Mechanisms and Translational Applications
-
批准号:9121124
-
项目类别:
-
资助金额:$3.0万
-
财政年份:2016
-
负责人:Robert F. Schwabe
-
依托单位:
HMGB1 as Link Between Hepatocellular Injury and HCC
-
批准号:9888333
-
项目类别:
-
资助金额:$44.38万
-
财政年份:2016
-
负责人:Robert F. Schwabe
-
依托单位:
HMGB1 as Link Between Hepatocellular Injury and HCC
-
批准号:9258403
-
项目类别:
-
资助金额:$44.38万
-
财政年份:2016
-
负责人:Robert F. Schwabe
-
依托单位:
Hepatic Stellate Cells and Liver Cancer
-
批准号:9003035
-
项目类别:
-
资助金额:$35.83万
-
财政年份:2015
-
负责人:Robert F. Schwabe
-
依托单位:
Hepatic Stellate Cells and Liver Cancer
-
批准号:8801797
-
项目类别:
-
资助金额:$37.02万
-
财政年份:2015
-
负责人:Robert F. Schwabe
-
依托单位:
Promotion of Hepatocellular Carcinoma by Myofibroblasts
-
批准号:8256908
-
项目类别:
-
资助金额:$18.75万
-
财政年份:2011
-
负责人:Robert F. Schwabe
-
依托单位:
Promotion of Hepatocellular Carcinoma by Myofibroblasts
-
批准号:8555377
-
项目类别:
-
资助金额:$18.03万
-
财政年份:2011
-
负责人:Robert F. Schwabe
-
依托单位:
海外基金